JPRN-UMIN000007167已完成1 期
Phase I/II clinical trial of immunoRFA with OK-432 for patients with lung cancer - Phase I/II clinical trial of immunoRFA for patients with lung cancer
Osaka City University, Department of Diagnostic and Interventional Radiology, Japan0 个研究点目标入组 36 人开始时间: 2012年2月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The following patients must be excluded: 1)Patients with bleeding tendency 2)Patients who cannot take a CAT scan 3)Patients with the past history of severe allergic reactions for OK-432 4)Patients with the past history of severe allergic reactions for Penicillin 5)Patients who are judged inappropriate for the clinical trial by doctors.
研究者
相似试验
招募中
1 期
Phase 1/2 clinical trial of immunotherapy with fusions of tumor cells and dendritic cells for pediatric refractory brain tumorPediatric refractory brain tumorJPRN-UMIN000031312Jikei University School of Medicine20
进行中（未招募）
1 期
Safety and immunogenicity of RNA-based vaccines against SARS-CoV-2 variants in healthy participantsProtection against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2).MedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 23.0Level: HLTClassification code 10084510Term: Coronavirus infectionsSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 23.1Level: LLTClassification code 10084529Term: 2019 novel coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2021-003458-22-DEBioNTech SE1,470
招募中
不适用
Investigator Clinical Phase 1/2 Study of Immunotherapy Using Autologous Killer Cell in Patients with Recurrent GlioblastomaKCT0003815Bundang CHA General Hospital23
进行中（未招募）
1 期
Evaluate the efficacy and safety la vacuna hexavalente (Hexyon) in preterm infantsVaccines, Bacterial and viral vaccines combinedEUCTR2018-004581-34-ESFundación Instituto Hispalense de Pediatría140
进行中（未招募）
不适用
A Phase II trial evaluating the immunological and clinical efficay and safety of HER-2 Protein Autovac(TM) monotherapy in patients with metastatic breast cancer - NAFemale patients with histologically proven metastatic or locally advanced breast cancer who have HER-2 overexpression in the primary tumour and/or a metastatic lesion.EUCTR2004-000838-36-HUPharmexa A/S60